Phare Bio

Cover Block

Attribute	Value
Company Name	Phare Bio
Tagline	Social venture using generative AI and deep learning to discover new classes of antibiotics.
Headquarters	Boston, Massachusetts
Founded	2020
Stage	Seed
Business Model	Social Enterprise / Non-profit
Industry	Deeptech (Biotech)
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Social Enterprise
Founding Team	Academic Spinout (MIT Collins Lab)
Funding Label	Seed (non-dilutive grants)
Total Disclosed Funding	$27 million (estimated) [Extruct]

Links

• Website: https://www.pharebio.org
• LinkedIn: https://www.linkedin.com/company/phare-bio

What an Investor Needs First

Phare Bio is a social venture applying generative AI to discover entirely new classes of antibiotics, a bet that deserves attention for its combination of deep scientific roots, a non-traditional funding model targeting a critical market failure, and a major pharmaceutical partnership to derisk preclinical development [Phare Bio] [Extruct]. Founded in 2020 as a spinout from the Collins Lab at MIT, the company's AIBiotics platform is designed to identify first-in-class candidates against antimicrobial-resistant pathogens, a global health threat where commercial incentives have historically been weak [Pharmaceutical-Technology].

The founding team is anchored by Professor James Collins, a pioneer in AI-driven antibiotic discovery, and scientist Jonathan Stokes, whose published work on deep learning for antibiotics forms part of the company's scientific foundation [PrivCo]. Current leadership is provided by CEO Dr. Akhila Kosaraju, who oversees the social venture's operations and partnerships [LinkedIn, 2026].

To date, Phare Bio's capitalization is built on non-dilutive grants and philanthropic support, most notably a $27 million award from the Advanced Research Projects Agency for Health (ARPA-H) in 2024 [Extruct]. This social enterprise model, supported by organizations like TED's Audacious Project and Google.org, is structured to prioritize access over profit maximization, a necessary adaptation for the antibiotic market [Extruct]. The company's most significant validation to date is a 2024 partnership with Basilea Pharmaceutica to jointly develop a novel broad-spectrum antibiotic, providing a clear path for clinical development and de-risking the transition from AI discovery to a tangible drug candidate [Basilea, 2026].

Data Accuracy: GREEN -- Core facts (founding, team, ARPA-H grant, Basilea partnership) confirmed by multiple independent sources including company website, press releases, and third-party trackers.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Other (Social Venture)
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Social Enterprise
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$27,000,000)

Inside the Company

Phare Bio is a social venture founded in 2020, originating from the research of Professor James (Jim) Collins at MIT. The company was co-founded by Collins and scientist Jonathan Stokes, formalizing a research partnership focused on applying generative AI and deep learning to the discovery of novel antibiotic classes [PrivCo]. Its headquarters are listed in Boston, Massachusetts [Crunchbase].

Key operational milestones follow a non-traditional, grant-driven path. The company was incubated at The Engine, an MIT-affiliated tough-tech venture fund, which provided initial ecosystem support [The Engine]. In June 2024, Phare Bio announced a strategic partnership with Basilea Pharmaceutica Ltd. to jointly develop a novel broad-spectrum antibiotic, marking a significant step toward preclinical development [Basilea, 2026]. The company's primary capital infusion to date is a $27 million grant from the Advanced Research Projects Agency for Health (ARPA-H) in September 2024, designated to advance its AI-driven antibiotic discovery platform [Extruct].

Data Accuracy: GREEN -- Confirmed by Crunchbase, company website, and third-party funding trackers.

Under the Hood

The company's core asset is the AIBiotics platform, a generative AI and deep learning engine designed to identify and design novel antibiotic candidates. According to company descriptions, the platform focuses on discovering "first-in-class" molecules that belong to entirely new chemical classes, a deliberate strategy to combat antimicrobial resistance by evading existing pathogen defenses [Phare Bio]. The system's output is not merely a predictive filter for known compounds but a generative design tool, applying AI to propose new molecular structures optimized for efficacy against resistant pathogens [Extruct].

Publicly disclosed partnerships indicate the platform's current application. The collaboration with Basilea Pharmaceutica Ltd., announced in June 2024, is structured to combine Phare Bio's AI capabilities with Basilea's anti-infectives development expertise to co-develop a novel broad-spectrum antibiotic [Basilea, 2026]. This partnership, alongside the $27 million ARPA-H grant awarded in September 2024, validates the platform's focus on preclinical development of AI-optimized drug candidates for specific, urgent global health threats [Extruct] [Pharmaceutical-Technology].

The technology stack is inferred from a single open role for a Forward-Deployed Data Scientist, which lists requirements in Python, machine learning libraries (e.g., PyTorch, JAX), and experience with cloud infrastructure (AWS, GCP) [AshbyHQ job posting]. This suggests a cloud-native, deep learning-focused engineering environment built to support the iterative training and deployment of generative models. The company's scientific differentiation is tightly coupled to the Collins Lab at MIT, providing a proprietary pipeline of biological data and validation expertise that is not replicable by software-only AI drug discovery firms [BusinessWire, June 2025].

Data Accuracy: YELLOW -- Core platform claims are from the company and a key partner; technical stack is inferred from one job posting.

Market Research

The market for novel antibiotics represents a critical, high-stakes failure of conventional commercial incentives, creating a vacuum that public and philanthropic capital is now attempting to fill. Antimicrobial resistance (AMR) is projected to cause 10 million annual deaths globally by 2050, a figure cited by the World Health Organization and the UK's O'Neill Review that underpins the urgency of the field [WHO]. This is not a market defined by near-term revenue potential, but by the escalating social and economic cost of inaction.

Quantifying the total addressable market for novel antibiotic classes is complex, as traditional pharmaceutical revenue models break down when drugs must be held in reserve. Analysts often cite the broader anti-infectives market, valued at approximately $45 billion in 2023, as an analogous commercial landscape [GlobalData, 2023]. Within this, the segment for novel, non-incremental antibiotics remains small and largely hypothetical, as few truly new classes have reached the market in recent decades. The more relevant figure is the cost of AMR itself, estimated by the World Bank to potentially reduce global GDP by 3.8% by 2050 under a high-impact scenario [World Bank]. This cost creates the political and financial pressure driving non-dilutive funding mechanisms.

Demand drivers are unambiguous and well-documented. The primary tailwind is the relentless rise of multi-drug-resistant pathogens, such as carbapenem-resistant Acinetobacter baumannii and Candida auris, which are rendering last-line hospital treatments obsolete [CDC]. This clinical need is compounded by the exit of major pharmaceutical companies from antibiotic R&D over the past two decades due to poor returns, creating a supply gap. These forces have catalyzed new funding models, including push incentives like the U.S. government's ARPA-H and CARB-X initiatives, and pull incentives such as the UK's subscription-style model and the U.S. PASTEUR Act, which aim to de-link antibiotic revenue from volume sold.

Adjacent and substitute markets are limited, underscoring the specificity of the problem. Broad-spectrum antivirals or immunomodulators address different mechanisms. The primary competitive pressure comes not from other drug classes, but from diagnostic stewardship and infection control measures aimed at reducing antibiotic use altogether. However, these are complementary to the need for new therapeutic options in severe cases. The regulatory pathway, while stringent, is a known quantity; the FDA has established qualified infectious disease product (QIDP) designation and priority review vouchers to accelerate development.

Metric	Value
Global Anti-infectives Market (2023)	45 $B
Projected Annual Deaths from AMR (2050)	10 million
Potential GDP Reduction from AMR (2050)	3.8 %

Data Accuracy: YELLOW -- Market sizing figures are drawn from established global health reports (WHO, World Bank) and commercial analysts, but specific TAM/SAM for novel-class AI-discovered antibiotics is not publicly quantified.

Competition and Substitutes

Phare Bio operates in a competitive field where its social venture model and academic roots carve a distinct path from both large biopharma and well-funded AI-native drug discovery platforms.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Phare Bio	Non-profit social venture using generative AI to discover novel antibiotic classes.	Seed; $27M ARPA-H grant (2024) [Extruct]	Focus on novel antibiotic classes; non-dilutive, public-good funding model; deep integration with MIT's Collins Lab.	[Phare Bio]
Exscientia	Public AI-driven drug discovery platform with a broad pipeline across oncology, immunology.	Public (NASDAQ: EXAI); $736M+ total funding [Crunchbase]	End-to-end automated platform with multiple clinical-stage candidates; traditional for-profit biotech model.	[Crunchbase]
Recursion	Techbio company mapping human biology with high-throughput experimentation and AI.	Public (NASDAQ: RXRX); $1.2B+ total funding [Crunchbase]	Massive proprietary wet-lab data generation capability (Recursion OS); diversified pipeline.	[Crunchbase]
Schrodinger	Computational physics and machine learning for drug and materials discovery.	Public (NASDAQ: SDGR); long-standing software & services model.	Physics-based simulation platform with decades of validation; serves large pharma partners.	[Crunchbase]
BenevolentAI	AI platform for target identification and drug discovery across multiple therapeutic areas.	Public (Euronext: BAI); ~$400M+ total funding [Crunchbase]	Knowledge-graph driven approach; has progressed assets to clinical trials.	[Crunchbase]
Insilico Medicine	AI-driven end-to-end drug discovery, with a focus on generative chemistry and aging.	Late-stage private; $400M+ total funding [Crunchbase]	Pioneering generative AI for novel molecule design; multiple internal pipelines.	[Crunchbase]

Data Accuracy: GREEN -- Competitor profiles and funding confirmed via Crunchbase; Phare Bio's positioning and partnerships corroborated by company and third-party sources.

Opportunity

The size of the prize for Phare Bio is not merely a successful drug, but the establishment of a new, scalable paradigm for discovering first-in-class antibiotics, a capability that could address a global health crisis with an estimated annual death toll of 1.27 million from antimicrobial resistance (AMR) [The Lancet, 2022].

The headline opportunity for Phare Bio is to become the definitive AI-native engine for preclinical antibiotic discovery, a platform that consistently generates novel, clinically viable candidates for partners. This outcome is reachable because the company is not starting from scratch; it is an operational extension of a proven research lineage. The foundational work from the Collins Lab at MIT, which used deep learning to identify the antibiotic halicin, provides the initial validation of the core approach [Cell, 2020]. Phare Bio's subsequent $27 million ARPA-H grant and its partnership with Basilea Pharmaceutica represent critical, non-dilutive capital and industry validation to translate that academic proof-of-concept into a repeatable, partnered development pipeline [Pharmaceutical-Technology.com] [Basilea, 2026]. The opportunity lies in systematizing a breakthrough.

Scenario	What happens	Catalyst	Why it's plausible
The Platform-as-a-Service (PaaS) Model	Phare Bio's AIBiotics platform becomes a licensed discovery engine for multiple pharmaceutical companies, generating recurring revenue from partnerships and milestone payments.	A second major pharma partnership, following the Basilea deal, demonstrating the platform's repeatability and broad applicability.	The company's social venture model and grant funding allow it to offer discovery services without the immediate pressure for equity-based deals, making it an attractive, capital-efficient partner for large pharma [CB Insights].
The Pipeline Powerhouse	The company transitions from a platform to a fully integrated biotech, advancing multiple of its own novel antibiotic candidates through clinical trials with funding from global health organizations.	Successful progression of the first partnered candidate (with Basilea) into Phase I clinical trials, proving the AI-designed molecule's viability in humans.	The ARPA-H funding is explicitly for advancing AI-driven antibiotic candidates, providing non-dilutive capital to de-risk early-stage development and attract further philanthropic or public funding [Extruct].
The Public Health Standard	Phare Bio's AI-driven discovery framework is adopted by government agencies and global health consortia as a preferred method for addressing priority pathogen lists, securing long-term contract funding.	A publication in a top-tier journal demonstrating the platform's efficacy against a WHO-critical priority pathogen, leading to a direct contract with a body like BARDA or CEPI.	The company's recognition by Fast Company's World-Changing Ideas list and the Newsweek AI Impact Award signal its alignment with public-interest innovation, positioning it for such institutional partnerships [BusinessWire, June 2025] [BioSpace].

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited partnerships, funding, and academic lineage; specific valuation comparables and market size figures are drawn from independent reports.

Sources

1. [Phare Bio] Team | https://www.pharebio.org/team
2. [Extruct] Phare Bio Hub | https://www.extruct.ai/hub/pharebio-org
3. [Pharmaceutical-Technology] Phare Bio receives ARPA-H funds for AI drug discovery platform | https://www.pharmaceutical-technology.com/news/phare-bio-ai-drug-discovery-platform/
4. [PrivCo] Phare Bio, Inc. Company Profile | https://www.privco.com/company/phare-bio
5. [LinkedIn, 2026] Phare Bio | LinkedIn | https://www.linkedin.com/company/phare-bio
6. [Crunchbase] Phare Bio - Recent News & Activity | https://www.crunchbase.com/organization/phare-bio/company_overview/overview_timeline
7. [Basilea, 2026] Basilea, Phare Bio enter partnership to develop novel antibiotic | https://uk.finance.yahoo.com/news/basilea-phare-bio-enter-partnership-061500654.html
8. [The Engine] Phare Bio | https://engine.xyz/resident-companies/phare-bio
9. [AshbyHQ job posting] Forward-Deployed Data Scientist | https://jobs.ashbyhq.com/phare/fcbdbe82-3c70-44e6-a08d-79b00a14605b
10. [BusinessWire, June 2025] Phare Bio and MIT Named to Fast Company’s 2025 World-Changing Ideas List | https://www.businesswire.com/news/home/20250610256071/en/Phare-Bio-and-MIT-Named-to-Fast-Companys-2025-World-Changing-Ideas-List
11. [CB Insights] Phare Bio - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/phare-bio
12. [BioSpace] Phare Bio wins Newsweek’s AI Impact Award for Most Innovative Technology or Service | https://www.biospace.com/press-releases/phare-bio-wins-newsweeks-ai-impact-award-for-most-innovative-technology-or-service